Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

Author

BENJAMIN, Robert S¹ ; SCHÖFFSKI, Patrick² ; SKUBITZ, Keith¹⁰ ; MCCOY, Sheryl¹¹ ; SUN, Yu-Nien¹² ; LAURENCE BAKER, Daniel E. Stepan¹² ; HARTMANN, Jörg Thomas³ ; VAN OOSTEROM, Allan² ; BINH NGUYEN BUI⁴ ; DUYSTER, Justus⁵ ; SCHUETZE, Scott⁶ ; BLAY, Jean-Yves⁷ ; REICHARDT, Peter⁸ ; ROSEN, Lee S⁹
[1] Department of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Unit 450, Houston, TX 77030-4009, United States
[2] University Hospital Gasthuisberg, Leuven, Belgium
[3] Christian- Albrechts- Universität, Comprehensive Cancer Center North, Kiel, Germany
[4] Institut Bergonié, Bordeaux, France
[5] Technische Universitat München, Munich, Germany
[6] University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States
[7] HELIOS Klinikum, Bad Saarow, Germany
[8] Universite Claude Bernard and INSERM U590 Centre L. Berard and UJOMM Pavilion E, Hospital Ed. Herriot, Lyon, France
[9] Premiere Oncology, Santa Monica, CA, United States
[10] University of Minnesota, Minneapolis, MN, United States
[11] Amgen Inc., South San Francisco, CA, United States
[12] Amgen Inc., Thousand Oaks, CA, United States

Source

Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 1, pp 69-77, 9 p ; ref : 25 ref

CODEN

CCPHDZ

ISSN

0344-5704

Scientific domain

Medical oncology; Pharmacology drugs

Publisher

Springer, Heidelberg

Publication country

Germany

Document type

Article

Language

English

Author keyword

Angiogenesis GIST Imatinib Kit receptor Motesanib VEGF receptor

Keyword (fr)

Angiogenèse Anticancéreux Efficacité traitement Facteur croissance dérivé thrombocyte Facteur croissance endothélium vasculaire Gène onc cellulaire Homme Imatinib Malade Motésanib Néovascularisation Protooncogène Récepteur biologique Résistance Sécurité Toxicité Tumeur stromale gastro-intestinale Voie orale Cancer Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil digestif Pathologie de l'estomac Pathologie de l'intestin Protein-tyrosine kinase Transferases Tumeur maligne

Keyword (en)

Angiogenesis Antineoplastic agent Treatment efficiency Platelet derived growth factor Vascular endothelium growth factor C-Onc gene Human Imatinib Patient Motesanib Neovascularization Protooncogene Biological receptor Resistance Safety Toxicity Gastrointestinal stromal tumor Oral administration Cancer Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Digestive diseases Gastric disease Intestinal disease Protein-tyrosine kinase Transferases Malignant tumor

Keyword (es)

Angiogénesis Anticanceroso Eficacia tratamiento Factor crecimiento derivado plaqueta Factor crecimiento endotelio vascular Gen onc celular Hombre Imatinib Enfermo Motesanib Neovascularización Protooncogen Receptor biológico Resistencia Seguridad Toxicidad Tumor estromal gastrointestinal Vía oral Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato digestivo patología Estómago patología Intestino patología Protein-tyrosine kinase Transferases Tumor maligno

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors

Discipline

Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

24306297

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS